230 related articles for article (PubMed ID: 29482012)
1. Use of the intramuscular route to administer pentamidine isethionate in Leishmania guyanensis cutaneous leishmaniasis increases the risk of treatment failure.
Christen JR; Bourreau E; Demar M; Lightburn E; Couppié P; Ginouvès M; Prévot G; Gangneux JP; Savini H; de Laval F; Pommier de Santi V; Briolant S
Travel Med Infect Dis; 2018; 24():31-36. PubMed ID: 29482012
[TBL] [Abstract][Full Text] [Related]
2. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana.
Roussel M; Nacher M; Frémont G; Rotureau B; Clyti E; Sainte-Marie D; Carme B; Pradinaud R; Couppié P
Ann Trop Med Parasitol; 2006 Jun; 100(4):307-14. PubMed ID: 16762111
[TBL] [Abstract][Full Text] [Related]
3. [Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate].
Lightburn E; Morand JJ; Meynard JB; Kraemer P; Chaudier B; Pages F; Garnotel E; Patte JH; Banzet S; Dampierre H; Lepage J; Morillon M; Boutin JP; Hovette P; Chouc C
Med Trop (Mars); 2003; 63(1):35-44. PubMed ID: 12891748
[TBL] [Abstract][Full Text] [Related]
4. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.
Nacher M; Carme B; Sainte Marie D; Couppié P; Clyti E; Guibert P; Pradinaud R
Ann Trop Med Parasitol; 2001 Jun; 95(4):331-6. PubMed ID: 11454242
[TBL] [Abstract][Full Text] [Related]
5. Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.
Mans DR; Kent AD; Hu RV; Lai A Fat EJ; Schoone GJ; Adams ER; Rood EJ; Alba S; Sabajo LO; Lai A Fat RF; de Vries HJ; Schallig HD
Clin Exp Dermatol; 2016 Aug; 41(6):610-5. PubMed ID: 26648589
[TBL] [Abstract][Full Text] [Related]
6. An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region.
Gadelha EPN; Ramasawmy R; da Costa Oliveira B; Morais Rocha N; de Oliveira Guerra JA; Allan Villa Rouco da Silva G; Gabrielle Ramos de Mesquita T; Chrusciak Talhari Cortez C; Chrusciak Talhari A
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006850. PubMed ID: 30379814
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis.
Delobel P; Pradinaud R
J Antimicrob Chemother; 2003 May; 51(5):1319-20. PubMed ID: 12668576
[No Abstract] [Full Text] [Related]
8. Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects.
Henry K; Mayet A; Hernandez M; Frechard G; Blanc PA; Schmitt M; André N; Loreau JM; Ginouves M; Prévot G; Couppié P; Demar M; Blaizot R
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009938. PubMed ID: 34797836
[TBL] [Abstract][Full Text] [Related]
9. Using pentamidine to treat cutaneous leishmaniasis in children: a 10-year study in French Guiana.
Heleine M; Elenga N; Njuieyon F; Martin E; Piat C; Pansart C; Couppie P; Hernandez M; Demar M; Blaizot R
Clin Exp Dermatol; 2023 Jul; 48(8):913-915. PubMed ID: 37075241
[TBL] [Abstract][Full Text] [Related]
10. [Identification of Leishmania (V) guyanensis during recurrences of cutaneous leishmaniasis contracted in French Guyana].
Larriviere-Chouc C; De Pina JJ; Faraut-Gambarelli F; Morillon M; Normand P
Med Trop (Mars); 1996; 56(3):309. PubMed ID: 9026604
[No Abstract] [Full Text] [Related]
11. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.
Lai A Fat EJ; Vrede MA; Soetosenojo RM; Lai A Fat RF
Int J Dermatol; 2002 Nov; 41(11):796-800. PubMed ID: 12453009
[TBL] [Abstract][Full Text] [Related]
12. [Leishmania (Viannia) braziliensis Vianna, 1911 in French Guiana. Clinical, therapeutic and epidemiological considerations in the ninth human diagnosed case].
Raccurt CP; Pradinaud R; Couppie P; Moreau B; Pratlong F; Dedet JP; Cotellon P; Juminer B; Sainte-Marie D
Bull Soc Pathol Exot; 1996; 89(5):341-4. PubMed ID: 9264733
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients.
Hellier I; Dereure O; Tournillac I; Pratlong F; Guillot B; Dedet JP; Guilhou JJ
Dermatology; 2000; 200(2):120-3. PubMed ID: 10773699
[TBL] [Abstract][Full Text] [Related]
14. Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: An open, nonrandomized phase 2 trial.
Francesconi VA; Francesconi F; Ramasawmy R; Romero GAS; Alecrim MDGC
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006225. PubMed ID: 29481560
[TBL] [Abstract][Full Text] [Related]
15. In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment.
Bourreau E; Ronet C; Darsissac E; Lise MC; Marie DS; Clity E; Tacchini-Cottier F; Couppie P; Launois P
J Infect Dis; 2009 Feb; 199(4):576-9. PubMed ID: 19125672
[TBL] [Abstract][Full Text] [Related]
16. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis: case of a patient with 425 lesions.
Couppié P; Clyti E; Sainte-Marie D; Dedet JP; Carme B; Pradinaud R
Am J Trop Med Hyg; 2004 Nov; 71(5):558-60. PubMed ID: 15569784
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.
Neves LO; Talhari AC; Gadelha EP; Silva Júnior RM; Guerra JA; Ferreira LC; Talhari S
An Bras Dermatol; 2011; 86(6):1092-101. PubMed ID: 22281895
[TBL] [Abstract][Full Text] [Related]
18. [Epidemics of cutaneous leishmaniasis in military personnel working in French Guiana].
Banzet S
Med Trop (Mars); 2000; 60(3):297-302. PubMed ID: 11258067
[TBL] [Abstract][Full Text] [Related]
19. Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure.
Ginouvès M; Couppié P; Simon S; Bourreau E; Rogier S; Brousse P; Travers P; Pommier de Santi V; Demar M; Briolant S; Prévot G
Clin Microbiol Infect; 2021 Feb; 27(2):286.e1-286.e5. PubMed ID: 32380286
[TBL] [Abstract][Full Text] [Related]
20. High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.
Bourreau E; Prévot G; Gardon J; Pradinaud R; Launois P
J Infect Dis; 2001 Dec; 184(12):1628-30. PubMed ID: 11740743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
